Back to results
US 2026/0308282 A1Published application
Anti-nme antibody and method of treating cancer or cancer metastasis
AssigneeMinerva Biotechnologies Corporation
InventorsCynthia BAMDAD, Benoit SMAGGHE
Life of this patent
Estimating the term…
Abstract
The present application discloses anti-NMR antibodies and their use in treating or preventing diseases.
Claims23
An antibody that binds to NME7, comprising:
- (a) a heavy chain variable region (HCV) comprising the sequence of any one of SEQ ID NOs:
- 1160, 1162, 1164, and 1181;
- and a light chain variable region (LCV) comprising complementarity determining region (LC-CDR) 1 comprising the sequence of SEQ ID NO:
- 434, an LC-CDR2 comprising the sequence of SEQ ID NO:
- 435, and an LC-CDR3 comprising the sequence of SEQ ID NO:
- 436;
- or
- (b) an HCV comprising complementarity determining region (HC-CDR) 1 comprising the sequence of SEQ ID NO:
- 429, an HC-CDR2 comprising the sequence of SEQ ID NO:
- 430, and an HC-CDR3 comprising the sequence of SEQ ID NO:
- 431;
- and an LCV comprising the sequence of any one of SEQ ID NOs:
- 1166, 1168, 1170, 1183, 1185, and 1203.
10 more elements
A method of detecting a cancer, the method comprising measuring a level of an NME7 protein and/or a level of a nucleic acid encoding an NME7 protein or a fragment thereof in a patient sample.
-36. (canceled)
Dependencies are inferred from the claim text.